January 6, 2017 / 2:09 PM / 8 months ago

BRIEF-Adamas announces FDA acceptance of ADS-5102 new drug application

Jan 6 (Reuters) - Adamas Pharmaceuticals Inc :

* Adamas announces FDA acceptance of ADS-5102 new drug application for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease

* Adamas Pharmaceuticals Inc - PDUFA action date set for August 24, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below